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OBJECTIVES: Hereditary angioedema (HAE) is a rare and potentially serious dis-
ease. Due to its rarity, there are very few epidemiological and therapeutic data on
this disease. The objectives of this study were to generate new information describ-
ing HAE patients and their symptoms, costs of therapeutic management, and im-
pact on health-related quality of life (HRQoL). METHODS: A one-year retrospective
observational study was conducted involving 306 HAE patients across 19 French
medical centres. Data were collected on disease pathology, management,, re-
sources and health-related quality of life based on the SF-36. RESULTS: 64.1% of
patients had type I and/or II HAE, whilst 35.9% of patients had type III. The initial
symptoms appeared in adolescents for type I/II HAE and in young adults for type III
HAE. Across all HAE types, 87.4% of patients had already experienced at least one
severe (life threatening) event related to the pathology and had an average of 8.5
episodes in the prior year. Out of 883 episodes, hospitalisation was necessary in
11.4% of episodes. An ICU stay was needed in 13.8% of the hospitalised episodes,
and 3 of these stays necessitated intubation. 55.2% of the patients had ongoing
long-term prophylactic treatment. The annual per-patient cost of HAE episodes
(treatment, hospitalisation) was €4892 for type I/II and €3313 for type III. As com-
pared with a population of patients with allergies, patients suffering from HAE
have a decrease in their SF-36 scores in the areas of mental health and social
well-being, as well as in most domains of physical health. Notably, there is a sig-
nificant degradation in the SF-36 scores of patients when the number of episodes
increases. CONCLUSIONS: HAE is a disease which reduces the QoL and has a high
cost of treatment
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OBJECTIVES: To establish the relationship between cardiovascular risk (CVR) and
health-related quality of life (HRQoL), as well as the presence or absence of comor-
bidities, in a Spanish hypertensive population. METHODS: Epidemiological, cross-
sectional, multicenter study conducted in adult patients with essential hyperten-
sion of1 year of evolution. Patients were stratified in 5 categories according to the
CVR within 10 years (ESH/ESC, 2007): average, low added, moderate added, high
added and very high added CVR. HRQoL was measured by MINICHAL question-
naire. It comprises 2 domains (mental status and somatic manifestations) referred
to the past week. Overall scores range from 0 to 48, with higher scores representing
worse HRQoL. Presence of kidney and cardiovascular disease was evaluated.
RESULTS:A total of 6,654 patients (55.2% male) were assessed; median age (Q1, Q3)
63.0 (55.0, 72.0) years and time since hypertension diagnosis 6.5 (2.9, 10.7) years.
Average CVR was presented in 3.5%, low added in 13.6%, moderate added in 12.8%,
high added in 39.0% and very high added in 31.0% of patients. Overall MINICHAL
scores ranged from 4.0 (2.0, 8.0) in patients with average CVR to 11.0 (5.0, 18.0) in
patients with very high added CVR (p0.0001). Mental status and somatic mani-
festations domains scores ranged from 4.0 (1.0, 6.0) for average CVR to 8.0 (4.0, 13.0)
for very high added CVR, and from 0.0 (0.0, 2.0) for average CVR to 3.0 (1.0, 6.0) for
very high added CVR, respectively (p0.0001, in both cases). Overall MINICHAL
scores related to comorbidities (presence vs. absence) were: kidney disease 13.0
(7.0, 20.0) vs. 7.0 (3.0, 12.0) and cardiovascular disease 10.0 (5.0, 17.0) vs. 6.0 (3.0,
12.0), [p0.0001, in both cases]. CONCLUSIONS: Hypertensive patients with in-
creased CVR show significant worse HRQoL, in both mental status and somatic
manifestations domains. The presence of comorbidities is associated with a worse
HRQoL.
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OBJECTIVES: To analyze, for the first time in a large Spanish population of heart
failure pts, quality of life according to NYHA class II, III or IV using generic and
specific quality of life questionnaires. METHODS: A descriptive analysis of a mul-
ticenter, prospective observational study was performed. Pts who met inclusion
criteria were followed-up for a period of 12 months, with 3 visits programmed at
baseline, 6 months and 12 months. A total of 9 Spanish hospitals were involved in
the study. Questionnaires used to measure quality of life were: EQ-5D (generic
questionnaire), Minessotta living with heart failure- MLWHF (specific question-
naire) and Barthel Index (index of independence). RESULTS: A total of 330 pts
completed the study, 74.2% men, mean age was 62.9 years. 82.4% were in NYHA
class II, 16.4% NYHA class III and 1.2% NYHA class IV. A total of 20 pts died along the
period of study and 25 pts did not complete follow up. Significant differences were
observed in Barthel Index’s scores depending on class: class II 97.2  7.3 vs. Class
III-IV 91.4  14.3. Related to EQ-5D scores, individuals in class II had a mean value
of 0.8058  0.2048 (out of 1), and mean VAS value of 56.75  17.39 (out of 100).
Individuals in NYHA class III-IV had a mean value of 0.6135  0.3032 (out of 1) and
mean VAS value of 50.45  20.24 (out of 100). In a MLWHF questionnaire analyses,
pts in NYHA class II showed a mean score of 29.81 18.57 while pts in NYHA class
III-IV showed a mean score of 48.53  17.97. CONCLUSIONS: Chronic heart failure
patients in NYHA III and IV seemed to have a higher grade for physical disability
and worse health-related quality of life compared to patients in NYHA II and pop-
ulation of similar age.
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OBJECTIVES: ACS encompasses a spectrum of clinical presentations arising from
the progression of coronary artery disease including: unstable angina, non-ST seg-
ment elevation myocardial infarction (NSTEMI) and ST segment elevation myocar-
dial infarction (STEMI). The epidemiology of ACS varies internationally with shift-
ing incidence related to changes in lifestyle over time with broad implications for
health care systems. This review focuses on the economic and humanistic burden
of ACS. METHODS: A systematic electronic literature search was conducted to
identify published reports from 1965 through 2009 for ACS. Abstracts from the
initial search were reviewed to identify relevant papers. A full review was con-
ducted on articles that met general inclusion criteria. Reference lists were hand
searched to identify additional data. Studies not available in English were excluded.
RESULTS: ACS has been associated with large reductions in health-related quality
of life (HRQOL). Statistically significant declines in both the physical and social
functioning domains of the SF-36 have been reported for individuals with MI, in
particular, even years after the clinical event. However, such research is limited to
specific populations and particular clinical events with variable findings across
studies. Economic models have used utility values for ACS ranging from 0.61-0.93
(scale:0-1), depending upon age group and the clinical presentation of interest. A
study of five European countries shows that economic costs also vary. Annual cost
per patient ranged from €7,009 (UK) to €12,086 (Italy), with hospitalizations ac-
counting for 50% of the total, on average, and pharmaceutical expenditures com-
prising between 14% (Spain) to 23% (Germany) of ACS total cost. CONCLUSIONS:
ACS is a major source of morbidity and is associated with significant economic
burden on health care systems, though the estimated impact on HRQOL varies by
country, clinical presentation and metric. Future therapies for ACS may offer op-
portunities to reduce some of the economic and humanistic burden of ACS.
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OBJECTIVES: Data seldom report the experience of chronic stable angina (CSA)
directly perceived by patients. This qualitative work aimed to explore how patients
perceive CSA and its impact on their life in order to optimise communication
between the doctor and their patient in the decision-making process. METHODS:
CSA patients with and without professional activity and treated with the most
frequent anti-anginal therapeutic strategies were recruited. They were inter-
viewed face-to face, based on a guide specifically designed for the purpose of the
study including questions on knowledge and beliefs, as well as on impact and
management of CSA. Recruitment was completed when no additional information
was obtained with the last interview, thus reaching saturation of the themes in-
vestigated and allowing building the comprehensive picture of patients’
perception. RESULTS: Symptoms perceived by CSA patients are cardiac pain, fa-
tigue, breathlessness and increased heart rate. The disease impairs patients’ daily
life such as physical activities (in particular walking/running, climbing stairs/hill,
and holding/carrying heavy things), work, family, sexual and social life and leisure
activities, in addition to psychological/emotional status. In order to avoid symp-
toms, treated patients adopt coping strategies such as anticipating, avoiding or
segmenting efforts, limiting/taking things easy, getting help, initiating healthy life-
style. For those who live with partners they mainly delegate treatment manage-
ment to them. Saturation was reached with the sample size population (n25).
CONCLUSIONS: CSA has detrimental impact on patients’ lives. Treated patients
adopt various coping strategies to help them live with their disease and lessen their
symptoms. This exploratory work will help to better understand the disease and
assess benefits of anti-anginal treatment from a patient’s perspective. This is likely
to facilitate patient-doctor communication in the decision-making process.
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OBJECTIVES: The objective of this study was to compare attenders’ and non-at-
tenders’ preferences in relation to participation in lifestyle disease screening.
METHODS: During a screening trial of about 25,000 male citizens between the age
of 65 and 75, 2,119 invitees were sampled. The screening programme comprised a
test for abdominal aortic aneurysm, hypertension and peripheral artery disease,
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